TD139Galecto Biotech AB, a biotechnology company developing novel drugs to treat fibrotic conditions, inflammation, and other serious and rare human diseases, is currently conducting clinical trials for their novel formulation TD139. The experimental therapy is formulated for inhalation and is targeted at treating fibrotic conditions of the lungs, mostly in idiopathic pulmonary fibrosis (IPF).

History of TD139

Galecto Biotech has focused on galectins (a family of proteins which bind to β-galactoside sugars), which are actively involved in disease mechanisms. Galectins are a novel target for drug formulation and increase the scope for treatment options for “orphan” diseases.

Galectin-3 is a member of the galactoside binding lectins, either intra- or extracellularly, initiating inflammatory and fibrotic activity. The activation of macrophages and recruitment and activation of myofibroblasts, two key phenomena in fibrosis, are both dependent on galectin-3. Preclinical studies involving knockout of galectin-3 expression have shown considerable reduction in the amount of fibrotic tissue formation and prevention of fibrosis.

How TD139 Works

TD139 has been shown to be a potent inhibitor of the galactoside binding pockets of galectins, and has been successful in reducing fibrosis in organs and animal models. Being an inhalable formulation, it minimizes risks of side effects due to systemic exposure in the body. TD139 was initially developed by a team of scientists from Lund University in Sweden and Edinburgh University in Scotland in 2011.

Next Steps for TD139

Galecto Biotech is in Phase 1/2a randomized, double-blind, placebo-controlled, multi-center clinical trials in the United Kingdom. The primary endpoint is the safety and tolerability of TD139, with secondary endpoints including assessment of pharmacodynamics and efficiency of the drug in its anti-fibrotic activity.

Note: Pulmonary Fibrosis News is strictly a news and information website about the disease. It does not provide medical advice, diagnosis, or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.

Sign Up For Our IPF Clinical Trial Registry:

Sign Up For the Latest News On TD139:

Your Name (required)

Your Email (required)


  1. John Ritchey says:

    I am an IPF patient, diagnosed in June 2014. Currently using Espriet to slow the progression. Is it possible for a person in the USA to get involved in the Phase 2b dose ranging study?

    • Ed says:

      exactly,..thats what im saying!…or if not, how can we get our hands on some TD139 in the states..or by mail, ill pay whatever it takes!..sorry to hear that John, hang in there brutha, God Bless!

  2. Linda wysocki says:

    I have been diagnosed with IPF in October of 2017. It is mild to moderate status. I am active with minor restrictions and I am not on supplemental oxygen. I live in New York USA and would be interested in participating in your clinical trial as well as being kept informed of its progress

  3. Maureen Lake says:

    I was diagnosed in 2015 with IPF. I am presently being seen by Dr Daniel Dilling at Loyola. I discussed this trial with him, he was aware & said he was at a conference that presented it, but it’s not that easy to initiate a study here, but it is does happen. I am very interested in taking part in a study & would be able to travel if need be.

Leave a Comment

Your email address will not be published. Required fields are marked *